Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.06
CPHD's Cash to Debt is ranked lower than
65% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. CPHD: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
CPHD' s 10-Year Cash to Debt Range
Min: 0.99  Med: 12.96 Max: 11006.5
Current: 1.06
0.99
11006.5
Equity to Asset 0.46
CPHD's Equity to Asset is ranked lower than
73% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. CPHD: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
CPHD' s 10-Year Equity to Asset Range
Min: 0.45  Med: 0.73 Max: 0.92
Current: 0.46
0.45
0.92
F-Score: 5
Z-Score: 5.17
M-Score: -2.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -5.54
CPHD's Operating margin (%) is ranked lower than
54% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. CPHD: -5.54 )
Ranked among companies with meaningful Operating margin (%) only.
CPHD' s 10-Year Operating margin (%) Range
Min: -233.91  Med: -17.44 Max: 1.37
Current: -5.54
-233.91
1.37
Net-margin (%) -9.15
CPHD's Net-margin (%) is ranked lower than
55% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. CPHD: -9.15 )
Ranked among companies with meaningful Net-margin (%) only.
CPHD' s 10-Year Net-margin (%) Range
Min: -220.28  Med: -16.27 Max: 0.95
Current: -9.15
-220.28
0.95
ROE (%) -12.86
CPHD's ROE (%) is ranked lower than
57% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. CPHD: -12.86 )
Ranked among companies with meaningful ROE (%) only.
CPHD' s 10-Year ROE (%) Range
Min: -153.53  Med: -17.34 Max: 1.44
Current: -12.86
-153.53
1.44
ROA (%) -5.93
CPHD's ROA (%) is ranked lower than
52% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. CPHD: -5.93 )
Ranked among companies with meaningful ROA (%) only.
CPHD' s 10-Year ROA (%) Range
Min: -61.04  Med: -12.32 Max: 1.04
Current: -5.93
-61.04
1.04
ROC (Joel Greenblatt) (%) -14.29
CPHD's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. CPHD: -14.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPHD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -619.62  Med: -97.74 Max: 5.58
Current: -14.29
-619.62
5.58
Revenue Growth (3Y)(%) 17.30
CPHD's Revenue Growth (3Y)(%) is ranked higher than
83% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. CPHD: 17.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CPHD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -15.4  Med: 18.70 Max: 56.7
Current: 17.3
-15.4
56.7
» CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CPHD Guru Trades in Q3 2014

Columbia Wanger 7,745,200 sh (+3.73%)
Ron Baron 913,196 sh (+1.18%)
PRIMECAP Management 2,255,200 sh (unchged)
Mario Gabelli 234,500 sh (-0.21%)
» More
Q4 2014

CPHD Guru Trades in Q4 2014

PRIMECAP Management 2,310,100 sh (+2.43%)
Mario Gabelli 233,500 sh (-0.43%)
Ron Baron 884,701 sh (-3.12%)
Columbia Wanger 7,203,300 sh (-7.00%)
» More
Q1 2015

CPHD Guru Trades in Q1 2015

Jim Simons 51,950 sh (New)
PRIMECAP Management 2,323,600 sh (+0.58%)
Mario Gabelli 233,500 sh (unchged)
Ron Baron 860,003 sh (-2.79%)
Columbia Wanger 6,492,300 sh (-9.87%)
» More
Q2 2015

CPHD Guru Trades in Q2 2015

RS Investment Management 310,520 sh (New)
RS Investment Management 310,520 sh (New)
Jim Simons 295,250 sh (+468.33%)
PRIMECAP Management 2,335,100 sh (+0.49%)
Ron Baron 846,834 sh (-1.53%)
Mario Gabelli 214,500 sh (-8.14%)
Columbia Wanger 5,582,372 sh (-14.02%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 256.41
CPHD's Forward P/E is ranked lower than
97% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.12 vs. CPHD: 256.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 9.66
CPHD's P/B is ranked lower than
87% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. CPHD: 9.66 )
Ranked among companies with meaningful P/B only.
CPHD' s 10-Year P/B Range
Min: 2.25  Med: 8.48 Max: 14.01
Current: 9.66
2.25
14.01
P/S 6.99
CPHD's P/S is ranked lower than
74% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. CPHD: 6.99 )
Ranked among companies with meaningful P/S only.
CPHD' s 10-Year P/S Range
Min: 1.76  Med: 6.84 Max: 13.39
Current: 6.99
1.76
13.39
POCF 139.84
CPHD's POCF is ranked lower than
96% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. CPHD: 139.84 )
Ranked among companies with meaningful POCF only.
CPHD' s 10-Year POCF Range
Min: 45.31  Med: 145.18 Max: 1642.33
Current: 139.84
45.31
1642.33
Current Ratio 3.87
CPHD's Current Ratio is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. CPHD: 3.87 )
Ranked among companies with meaningful Current Ratio only.
CPHD' s 10-Year Current Ratio Range
Min: 1.49  Med: 3.10 Max: 15.23
Current: 3.87
1.49
15.23
Quick Ratio 2.87
CPHD's Quick Ratio is ranked higher than
61% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. CPHD: 2.87 )
Ranked among companies with meaningful Quick Ratio only.
CPHD' s 10-Year Quick Ratio Range
Min: 0.89  Med: 2.35 Max: 14.9
Current: 2.87
0.89
14.9
Days Inventory 196.94
CPHD's Days Inventory is ranked lower than
88% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. CPHD: 196.94 )
Ranked among companies with meaningful Days Inventory only.
CPHD' s 10-Year Days Inventory Range
Min: 57.37  Med: 148.33 Max: 629.87
Current: 196.94
57.37
629.87
Days Sales Outstanding 55.45
CPHD's Days Sales Outstanding is ranked higher than
60% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. CPHD: 55.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPHD' s 10-Year Days Sales Outstanding Range
Min: 40.78  Med: 58.71 Max: 124.41
Current: 55.45
40.78
124.41

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 36.49
CPHD's Price/Net Current Asset Value is ranked lower than
88% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.45 vs. CPHD: 36.49 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPHD' s 10-Year Price/Net Current Asset Value Range
Min: 2.35  Med: 16.73 Max: 50.57
Current: 36.49
2.35
50.57
Price/Tangible Book 11.79
CPHD's Price/Tangible Book is ranked lower than
83% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. CPHD: 11.79 )
Ranked among companies with meaningful Price/Tangible Book only.
CPHD' s 10-Year Price/Tangible Book Range
Min: 2.1  Med: 10.56 Max: 20.53
Current: 11.79
2.1
20.53
Price/Projected FCF 34.26
CPHD's Price/Projected FCF is ranked lower than
97% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. CPHD: 34.26 )
Ranked among companies with meaningful Price/Projected FCF only.
CPHD' s 10-Year Price/Projected FCF Range
Min: 17.93  Med: 33.70 Max: 94.71
Current: 34.26
17.93
94.71
Price/Median PS Value 1.03
CPHD's Price/Median PS Value is ranked higher than
56% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. CPHD: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
CPHD' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.13 Max: 4.11
Current: 1.03
0.35
4.11
Earnings Yield (Greenblatt) (%) -0.84
CPHD's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. CPHD: -0.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPHD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.91  Med: 0.20 Max: 0.4
Current: -0.84
-0.91
0.4

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 545 635
EPS($) -0.14 0.20
EPS without NRI($) -0.14 0.20

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:XEP.Germany,
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
» More Articles for CPHD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 
CEPHEID Reports Operating Results (10-Q) Aug 04 2010 
CEPHEID Reports Operating Results (10-Q) May 04 2010 

More From Other Websites
CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers Aug 26 2015
CEPHEID Financials Aug 20 2015
Cepheid Announces CFO Change Aug 13 2015
CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Aug 13 2015
Cepheid Announces CFO Change Aug 13 2015
10-Q for Cepheid Aug 11 2015
Waters Corp. Earnings Q2*, 2015 Aug 11 2015
CEPHEID Files SEC form 10-Q, Quarterly Report Aug 07 2015
Cepheid to Webcast Upcoming Financial Presentations Aug 06 2015
Cepheid to Webcast Upcoming Financial Presentations Aug 06 2015
'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms Jul 29 2015
World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC Jul 28 2015
World's Most Portable Molecular Diagnostics System Unveiled at AACC Jul 28 2015
World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC Jul 28 2015
World's Most Portable Molecular Diagnostics System Unveiled at AACC Jul 28 2015
CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and... Jul 24 2015
Edited Transcript of CPHD earnings conference call or presentation 23-Jul-15 9:00pm GMT Jul 24 2015
Cepheid Q2 Loss Narrower than Expected, Guidance Revised - Analyst Blog Jul 24 2015
Cepheid reports 2Q loss Jul 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK